StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96−0.10 (-1.24%)

Close on Nov 17, 2026Market cap $1.31BP/E –Yield –

Novavax pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Novavax's pe ratio was 3.1× on Apr 30, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 20263.1×−0.7
2025Dec 31, 20253.8×–

More Novavax figures

See a number that looks wrong?